凯莱英: 《凯莱英医药集团（天津）股份有限公司章程》

Core Points - The articles outline the regulations and governance structure of Asymchem Laboratories (Tianjin) Co., Ltd., emphasizing the protection of the rights of shareholders and creditors [1][4] - The company was established in Tianjin and registered on September 20, 2011, following the approval of the Tianjin Economic and Technological Development Zone Management Committee [2][3] - The company has undergone public offerings, including the issuance of 22,863,500 shares of ordinary stock and 19,680,900 H shares, with the latter listed on the Hong Kong Stock Exchange [2][3][8] Company Structure - The registered capital of the company is 360,593,720 RMB, and it operates as a permanent limited liability company [3][4] - The company is governed by a board of directors, with the chairman serving as the legal representative [3][4] - The company’s assets are divided into equal shares, and shareholders are liable only to the extent of their subscribed shares [3][4] Business Objectives and Scope - The company's business objective is to develop and produce high-tech pharmaceutical raw materials and biotechnology products, aiming to enhance its competitiveness in the international market [5][6] - The company engages in the research and development of new drug technologies and related technical consulting services [5][6] Share Capital and Structure - The company has a total of 264,281,818 shares, with 333,040,460 A shares and 19,680,900 H shares, indicating a significant proportion of domestic shares [7][8] - The shares are issued in accordance with principles of openness, fairness, and justice, ensuring equal rights for all shareholders of the same class [6][7] Shareholder Rights and Obligations - Shareholders have the right to receive dividends, participate in shareholder meetings, and access company information [25][26] - Shareholders holding more than 5% of shares must report any pledges of their shares to the company [29][30] - The company has provisions for shareholders to sue the company or its directors in case of violations of laws or the company’s articles [28][29]